Issue Archive
Table of Contents
Blood Advances Talks
IMMUNOBIOLOGY
MYELOID NEOPLASIA
Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Clinical Trials & Observations
THROMBOSIS AND HEMOSTASIS
The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages
-
Cover Image
Cover Image
COVER FIGURE
Genomic distribution of 51 clonal chromosomal mosaic events detected in blood DNA by whole-genome single-nucleotide polymorphism arrays in 130 patients with Fanconi anemia (FA). The circular plot shows the chromosomal location of each of the 51 mosaic events detected (red bars, losses; blue bars, gains; orange bars, multicopy gains; and green bars, copy-neutral events or uniparental disomies). The detected frequency of clonal events is over 100-fold higher in individuals with FA (n = 130) than in age-matched healthy controls (n = 15 743). These clonal events reflect the cytogenetic status of the bone marrow, and their presence is strongly associated with increased cancer risk and poor survival. See the article by Reina-Castillón et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals